Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With HER2- Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03805841
What this trial is testing

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Who this might be right for
NSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIIC+5 more
Rain Oncology Inc 41
Testing effectiveness (Phase 2)UnknownNCT05847764
What this trial is testing

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Who this might be right for
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsRC48+1 more
Sun Yat-sen University 95
Early research (Phase 1)Active Not RecruitingNCT02432963
What this trial is testing

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Who this might be right for
Adult Solid NeoplasmBladder CarcinomaColon Carcinoma+14 more
City of Hope Medical Center 11
Not applicableAvailableNCT06761976
What this trial is testing

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Who this might be right for
Advanced Non-small Cell Lung CancerCancer
Bayer
Not applicableUnknownNCT05411276
What this trial is testing

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

Who this might be right for
HER2 Mutant Non-small Cell Lung Cancer
Beijing Chest Hospital 15
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Early research (Phase 1)Active Not RecruitingNCT05650879
What this trial is testing

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Who this might be right for
HER2 Mutant Non-small Cell Lung CancerHER2-positive Metastatic Breast CancerHER2 Gene Mutation+1 more
Enliven Therapeutics 198
Testing effectiveness (Phase 2)Ended earlyNCT04402008
What this trial is testing

Study of Poziotinib in Japanese Patients With NSCLC

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 42
Large-scale testing (Phase 3)Study completedNCT04447118
What this trial is testing

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Who this might be right for
Non-squamous NSCLCHER2 Exon 20 Mutation
Jiangsu HengRui Medicine Co., Ltd. 151
Testing effectiveness (Phase 2)UnknownNCT05435274
What this trial is testing

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small-Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 380
Testing effectiveness (Phase 2)Study completedNCT03845270
What this trial is testing

Her2-positive Lung Cancer Treated With Dedicated Drug

Who this might be right for
Non Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer Stage IIIHER2 Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 46
Testing effectiveness (Phase 2)Looking for participantsNCT05099172
What this trial is testing

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation
Bayer 400
Testing effectiveness (Phase 2)Study completedNCT02834936
What this trial is testing

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Who this might be right for
Non Small Cell Lung
Jiangsu HengRui Medicine Co., Ltd. 60
Testing effectiveness (Phase 2)UnknownNCT02535507
What this trial is testing

Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Tongji University 40
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04579380
What this trial is testing

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Who this might be right for
Uterine NeoplasmsUterine Cervical NeoplasmsBiliary Tract Neoplasms+3 more
Seagen, a wholly owned subsidiary of Pfizer 217
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05745740
What this trial is testing

RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Who this might be right for
Non-small Cell Lung Cancer
RemeGen Co., Ltd. 26
Early research (Phase 1)Looking for participantsNCT07361562
What this trial is testing

A Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more
Cogent Biosciences, Inc. 100
Not applicableStudy completedNCT00896909
What this trial is testing

HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598

Who this might be right for
Lung Cancer
ECOG-ACRIN Cancer Research Group 44
Testing effectiveness (Phase 2)Ended earlyNCT03318939
What this trial is testing

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 648
Next Page